Exhibit 99.1
PDL BioPharma, Inc.
SPC Status Report
Country | Drug | Underlying Patent No. | SPC App. No. |
Austria | HERCEPTIN® (Trastuzumab) | E133452 | SZ36/2000 |
Belgium | HERCEPTIN® (Trastuzumab) | EP0451216 | 2000C/026 |
Germany | HERCEPTIN® (Trastuzumab) | 68925536.5 | 10075038.9 |
Denmark | HERCEPTIN® (Trastuzumab) | PR174317 | CA 2003 00007 |
Spain | HERCEPTIN® (Trastuzumab) | 2081974T3 | C200000026 |
Finland | HERCEPTIN® (Trastuzumab) | FI108797 | L2002 0008 |
France | HERCEPTIN® (Trastuzumab) | EP0451216 | 00C0035 |
Great Britain | HERCEPTIN® (Trastuzumab) | GB0451216 | SPC/GB00/032 |
Greece | HERCEPTIN® (Trastuzumab) | 1001050 | 20000800025 |
Ireland | HERCEPTIN® (Trastuzumab) | 82755 | 2003/006 |
Italy | HERCEPTIN® (Trastuzumab) | EP0451216 | UB2000CCP708 |
Luxembourg | HERCEPTIN® (Trastuzumab) | EP0451216 | 90676 |
Netherlands | HERCEPTIN® (Trastuzumab) | EP0451216 | 300023 |
Norway | HERCEPTIN® (Trastuzumab) | 310473 | SPC/NO2001024 |
Portugal | HERCEPTIN® (Trastuzumab) | PT 92758 | 79 |
Sweden | HERCEPTIN® (Trastuzumab) | SE0451216 | 0090024-1 |
Austria | XOLAIR® (Omalizumab) | E133452 | SZ42/2005 |
Belgium | XOLAIR® (Omalizumab) | EP0451216 | 2005C/038 |
Switzerland | XOLAIR® (Omalizumab) | EP0451216 | C00451216/04 |
Germany | XOLAIR® (Omalizumab) | 68925536.5 | 122005000057.40 |
Denmark | XOLAIR® (Omalizumab) | PR174317 | CA 2005 00051 |
Spain | XOLAIR® (Omalizumab) | 2081974T3 | C200500046 |
Finland | XOLAIR® (Omalizumab) | FI108797 | L20050028 |
France | XOLAIR® (Omalizumab) | EP0451216 | 05C0046 |
Great Britain | XOLAIR® (Omalizumab) | GB0451216 | SPC/GB05/052 |
Hungary | XOLAIR® (Omalizumab) | 211174 | S0500022 |
Ireland | XOLAIR® (Omalizumab) | 82755 | 2005/031 |
Italy | XOLAIR® (Omalizumab) | EP0451216 | UB2006CCP903 |
Luxembourg | XOLAIR® (Omalizumab) | EP0451216 | 91208 |
Netherlands | XOLAIR® (Omalizumab) | EP0451216 | 300213 |
Norway | XOLAIR® (Omalizumab) | 310473 | SPC/NO2005026 |
Portugal | XOLAIR® (Omalizumab) | PT 92758 | 212 |
Sweden | XOLAIR® (Omalizumab) | SE0451216 | 0590038-6 |
Slovenia | XOLAIR® (Omalizumab) | SI 8912489 | C-200640004 |
Austria | AVASTIN® (Bevacizumab) | E133452 | SZ 6/2005 |
Belgium | AVASTIN® (Bevacizumab) | EP0451216 | 2005C/004 |
Switzerland | AVASTIN® (Bevacizumab) | EP0451216 | C00451216/03 |
Germany | AVASTIN® (Bevacizumab) | 68925536.5 | 12 2005 000 007.8 |
PDL BioPharma, Inc.
SPC Status Report
Country | Drug | Underlying Patent No. | SPC App. No. |
Denmark | AVASTIN® (Bevacizumab) | PR174317 | CA 2005 00006 |
Spain | AVASTIN® (Bevacizumab) | 2081974T3 | C200500004 |
Finland | AVASTIN® (Bevacizumab) | FI108797 | L20050004 |
France | AVASTIN® (Bevacizumab) | EP0451216 | 05C0004 |
Great Britain | AVASTIN® (Bevacizumab) | GB0451216 | SPC/GB05/009 |
Hungary | AVASTIN® (Bevacizumab) | 211174 | S0500005 |
Ireland | AVASTIN® (Bevacizumab) | 82755 | 2005/007 |
Italy | AVASTIN® (Bevacizumab) | EP0451216 | CU-B2005CCP865 |
Luxembourg | AVASTIN® (Bevacizumab) | EP0451216 | 91 139 |
Netherlands | AVASTIN® (Bevacizumab) | EP0451216 | 300173 |
Norway | AVASTIN® (Bevacizumab) | 310473 | SPC/NO2005005 |
Portugal | AVASTIN® (Bevacizumab) | PT 92758 | 188 |
Sweden | AVASTIN® (Bevacizumab) | SE0451216 | 0590004-8 |
Slovenia | AVASTIN® (Bevacizumab) | SI 8912489 | C-200540007 |
Austria | TYSABRI® (natalizumab) | E133452 | SZ26/2006 |
Belgium | TYSABRI® (natalizumab) | EP0451216 | 2006C/024 |
Germany | TYSABRI® (natalizumab) | 68925536.5 | 122006000036.4 |
Denmark | TYSABRI® (natalizumab) | PR174317 | CA 200600022 |
Spain | TYSABRI® (natalizumab) | 2081974T3 | C200600026 |
Finland | TYSABRI® (natalizumab) | FI108797 | L20060010 |
France | TYSABRI® (natalizumab) | EP0451216 | 06C0028 |
Great Britain | TYSABRI® (natalizumab) | GB0451216 | SPC/GB/06/027 |
Hungary | TYSABRI® (natalizumab) | 211174 | S0600007 |
Ireland | TYSABRI® (natalizumab) | 82755 | 2006/027 |
Italy | TYSABRI® (natalizumab) | EP0451216 | C-UB2006CCP929 |
Luxembourg | TYSABRI® (natalizumab) | EP0451216 | 91272 |
Netherlands | TYSABRI® (natalizumab) | EP0451216 | 300239 |
Norway | TYSABRI® (natalizumab) | 310473 | SPC/NO2006009 |
Portugal | TYSABRI® (natalizumab) | PT 92758 | 235 |
Sweden | TYSABRI® (natalizumab) | SE0451216 | 0690023-7 |
Slovenia | TYSABRI® (natalizumab) | SI 8912489 | C-200640013 |
Switzerland | TYSABRI® (natalizumab) | EP0451216 | C00451216/05 |
Austria | LUCENTIS® (Ranibizumab) | E133452 | SZ36/2007 |
Belgium | LUCENTIS® (Ranibizumab) | EP0451216 | 2007C/030 |
Bulgaria | LUCENTIS® (Ranibizumab) | BG61095 | 07/041 |
Germany | LUCENTIS® (Ranibizumab) | 68925536.5 | 122007000037.5 |
Denmark | LUCENTIS® (Ranibizumab) | PR174317 | CA 2007 00029 |
Spain | LUCENTIS® (Ranibizumab) | 2081974T3 | C200700020 |
PDL BioPharma, Inc.
SPC Status Report
Country | Drug | Underlying Patent No. | SPC App. No. |
Finland | LUCENTIS® (Ranibizumab) | FI108797 | L20070013 |
France | LUCENTIS® (Ranibizumab) | EP0451216 | 07C0029 |
Great Britain | LUCENTIS® (Ranibizumab) | GB0451216 | SPC/GB07/033 |
Hungary | LUCENTIS® (Ranibizumab) | 211174 | S070003 |
Ireland | LUCENTIS® (Ranibizumab) | 82755 | 2007/019 |
Italy | LUCENTIS® (Ranibizumab) | EP0451216 | UB2007CCP969 |
Luxembourg | LUCENTIS® (Ranibizumab) | EP0451216 | 91333 |
Netherlands | LUCENTIS® (Ranibizumab) | EP0451216 | 300279 |
Norway | LUCENTIS® (Ranibizumab) | 310473 | SPC/NO2007006 |
Portugal | LUCENTIS® (Ranibizumab) | PT 92758 | 269 |
Sweden | LUCENTIS® (Ranibizumab) | SE0451216 | 0790030-1 |
Slovenia | LUCENTIS® (Ranibizumab) | SI 8912489 | C-200740008 |
3